Prediction of reversible myocardial dysfunction by positron emission tomography, low-dose dobutamine echocardiography, resting ECG, and exercise testing

Metabolic Scar Assessment with 18F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites

Background: Functional/molecular imaging characteristics of ischemic ventricular tachycardia (VT) substrate are incompletely understood. Objective: Compare regional ¹⁸F-FDG - PET tracer uptake with detailed electroanatomic maps (EAM) in a more extensive series of post-infarction VT patients to define metabolic properties of the VT substrate/successful ablation sites. Methods: 3D metabolic left ventricular (LV) reconstructions were created from perfusion-normalized ¹⁸F-FDG images in consecutive patients undergoing VT ablation. Metabolic defects were defined as severe (<50% uptake) or moderate (50-70% uptake) referenced to the maximal 17-segmental uptake. Color-coded PET scars reconstructions were co-registered with corresponding high-resolution 3D EAM. Results: All 56 patients had ischemic cardiomyopathy (EF=29±12%). Severe PET defect (<50%) was larger than EAM voltage scar (<0.5mV) with 63.0±48.4cm² vs. 13.8±33.1cm² (p<0.001). Similarly, moderate/severe PET defect (‎≤‎70%) was larger than areas with abnormal voltage (≤1.5mV) measuring 105.1±67.2cm² vs. 56.2±62.6cm² (p<0.001). Analysis of bipolar voltage (n = 23,389 mapping-points) showed decreased voltage among PET <50% (n = 10,364; 0.5±0.3mV) to PET 50-70% (n = 5,243; 1.5±0.9mV, p<0.01) with normal voltage among PET normal areas >70% (n = 7,782, 3.2±1.3mV, p<0.001). Eighty-eight percent of VT channel/exit sites (n = 44) were metabolically abnormal (PET <50%: 78%; PET 50-70%: 10%), while 12% (n = 6) were in metabolically normal areas (PET>70%). Metabolic channels (n = 26) existed in 45% (n = 25) of patients with average length/width of 17.6±12.5mm/10.3±4.2mm. Metabolic channels were oriented apex/base (86%) predominantly, harboring VT channel/exit sites in 31%. Metabolic Rapid Transition Areas (RTA: >50% change of ¹⁸F-FDG tracer uptake/15mm) were detected in 59% (n = 33) co-localizing to VT channels/exit sites (15%) or its proximity (85%, 12.8±8.5mm). Metabolism-voltage mismatches (MVM) with PET<50%/voltage>1.5mV) were seen in 21% (n = 12) harboring VT channel/exit sites in 41% of patients. Conclusion: Abnormal ¹⁸F-FDG uptake categories can be detected using incremental 3D step-up reconstructions. They predicted decreasing bipolar voltages and VT channel/exit sites in ~90%. Additionally, functional imaging allowed detecting novel molecular tissue characteristics within the ischemic VT substrate such as metabolic channels, RTA, and MVM demonstrating intra-substrate heterogeneity and providing possible targets for imaging-guided ablation.

PET and PET/CT in cardiovascular disease

The present review provides an overview of the role of cardiac positron emission tomography in the diagnosis and management of cardiovascular disease. It expands on the relative advantages and disadvantages over other imaging modalities as well as the available evidence supporting its value in the diagnosis and management of patients with coronary artery disease, the assessment of myocardial viability, and evaluation of the cardiac sympathetic nervous system. Furthermore, the recent developments, such as the implementation of high-end computed tomography devices to form hybrid systems, and the advances of molecular imaging probes in experimental applications are briefly discussed.

F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)

OBJECTIVES

We conducted a randomized trial to assess the effectiveness of F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)-assisted management in patients with severe ventricular dysfunction and suspected coronary disease.

BACKGROUND

Such patients may benefit from revascularization, but have significant perioperative morbidity and mortality. F-18-fluorodeoxyglucose PET can detect viable myocardium that might recover after revascularization.

METHODS

Included were patients with severe left ventricular (LV) dysfunction and suspected coronary disease being considered for revascularization, heart failure, or transplantation work-ups or in whom PET was considered potentially useful. Patients were stratified according to recent angiography or not, then randomized to management assisted by FDG PET (n = 218) or standard care (n = 212). The primary outcome was the composite of cardiac death, myocardial infarction, or recurrent hospital stay for cardiac cause, within 1 year.

RESULTS

At 1 year, the cumulative proportion of patients who had experienced the composite event was 30% (PET arm) versus 36% (standard arm) (relative risk 0.82, 95% confidence interval [CI] 0.59 to 1.14; p = 0.16). The hazard ratio (HR) for the composite outcome, PET versus standard care, was 0.78 (95% CI 0.58 to 1.1; p = 0.15); for patients that adhered to PET recommendations for revascularization, revascularization work-up, or neither, HR = 0.62 (95% CI 0.42 to 0.93; p = 0.019); in those without recent angiography, for cardiac death, HR = 0.4 (95% CI 0.17 to 0.96; p = 0.035).

CONCLUSIONS

This study did not demonstrate a significant reduction in cardiac events in patients with LV dysfunction and suspected coronary disease for FDG PET-assisted management versus standard care. In those who adhered to PET recommendations and in patients without recent angiography, significant benefits were observed. The utility of FDG PET is best realized in this subpopulation and when adherence to recommendations can be achieved.

Hibernating myocardium: diagnosis and patient outcomes

Approximately 50% of the patients with chronic obstructive coronary artery disease resulting in chronic contractile dysfunction have hibernating myocardium and may benefit from revascularization. This pooled analysis describes the relative merits of dobutamine echocardiography, thallium-201 and technetium-99m scintigraphy, positron emission tomography, and magnetic resonance imaging, for the diagnosis of hibernating myocardium and prediction of patient outcomes.

Coronary artery bypass surgery in heart failure patients with chronic reversible and irreversible myocardial dysfunction: effect on heart rate variability

It is unknown whether surgical revascularization of viable and chronic reversibly dysfunctional myocardium in patients with heart failure is associated with a favorable effect on the autonomic control of heart rate. We studied 38 coronary artery bypass surgery (CABG) patients with an ejection fraction of 36 +/- 7%. Before CABG, the patients underwent 48-hour ambulatory electrocardiographic monitoring to measure heart rate variability (HRV), echocardiography to assess left ventricular function, and positron emission tomography and low-dose dobutamine echocardiography to assess viability. Six months after CABG, ambulatory electrocardiographic monitoring and echocardiography were repeated to assess HRV and recovery of left ventricular function. In spite of viable myocardium and recovery of left ventricular function following CABG, HRV indices were reduced 6 months postoperatively. A potential prognostic benefit gained by revascularizing patients with viability may occur in spite of deteriorated autonomic control of heart rate.